Revolution Medicines (RVMD)
(Delayed Data from NSDQ)
$40.15 USD
-0.53 (-1.30%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $40.13 -0.02 (-0.05%) 6:30 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Revolution Medicines, Inc. [RVMD]
Reports for Purchase
Showing records 21 - 40 ( 42 total )
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
CodeBreak 101c Positive Early Data; 2Q22 Financials; Modulating PT to $37
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
A Plethora of RAS(ON) Presentations at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
2021 Financial Results Reported; Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
RAS(ON) Inhibitor Portfolio Expansion; Initial RMC-5552 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
RAS(ON) Inhibitors Slated to Enter Clinic in 2022; 3Q21 Financials; Raising to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Two SHP2 Combo Trials Culled; 2Q21 Financials; Lowering PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
RMC-5552 May Exhibit Improved Profile vs. Prior mTORC Inhibitors; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
R&D Day Showcases Pipeline Advantages vs. Competitors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
1Q21 Financials Reported; Key Pipeline Catalysts Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
AACR Conference Highlights Revolution''s Burgeoning Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
RAS(ON) Inhibitor Retains Efficacy in the Face of KRAS Resistance Mutation Impacting RAS(OFF) Inhibitors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
RAS(ON) Program Comes Into Focus; 3Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Triple-Meeting Takeaways; New AstraZeneca Collaboration; Raising PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
RMC-4630 Dosing Further Optimized; R-D Day and AACR Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Revolution Medicines, Inc.
Industry: Medical - Drugs
Phase 1b RMC-4630 and AMG-510 Combo Trial Starts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R